{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:32:28Z","timestamp":1790573548494,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.euo.2025.04.018","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T11:15:06Z","timestamp":1752923706000},"page":"1030-1040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer"],"prefix":"10.1016","volume":"8","author":[{"given":"Niven","family":"Mehra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Sala Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio Eduardo","family":"Yanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsiu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Begbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd L.","family":"Saretsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer R.","family":"Ghate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hosius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.04.018_b0005","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.eururo.2018.12.015","article-title":"Health-related quality of life for abiraterone plus prednisone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: results from a phase II randomized trial","volume":"75","author":"Khalaf","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.018_b0010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0094-0143(02)00187-8","article-title":"The physical burden of prostate cancer","volume":"30","author":"Penson","year":"2003","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.euo.2025.04.018_b0015","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1002\/cncr.32414","article-title":"Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database","volume":"125","author":"Tablazon","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2025.04.018_b0020","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO clinical practice guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.04.018_b0025","doi-asserted-by":"crossref","first-page":"E506","DOI":"10.5489\/cuaj.8161","article-title":"2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: management of castration-resistant prostate cancer (CRPC)","volume":"16","author":"Saad","year":"2022","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euo.2025.04.018_b0030","unstructured":"PLUVICTO\u00ae (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use. October 2022. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2022."},{"key":"10.1016\/j.euo.2025.04.018_b0035","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.018_b0040","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap"},{"key":"10.1016\/j.euo.2025.04.018_b0045","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0090-4295(97)00459-7","article-title":"Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument","volume":"50","author":"Esper","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.04.018_b0050","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.018_b0055","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1524-4733.2008.00409.x","article-title":"Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy\u2014Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer","volume":"12","author":"Cella","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.euo.2025.04.018_b0060","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jval.2013.12.005","article-title":"Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer","volume":"17","author":"Skaltsa","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.euo.2025.04.018_b0065","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.euo.2025.04.018_b0070","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.euo.2025.04.018_b0075","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/pme.12299","article-title":"Assessing analgesic use in patients with advanced cancer: development of a new scale\u2014the Analgesic Quantification Algorithm","volume":"15","author":"Chung","year":"2014","journal-title":"Pain Med"},{"issue":"25","key":"10.1016\/j.euo.2025.04.018_b0080","article-title":"Patient-reported outcomes in KEYNOTE-921: pembrolizumab with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer","volume":"1","author":"Matsubara","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.04.018_b0085","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(22)00017-1","volume":"23","author":"Thiery-Vuillemin","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.04.018_b0090","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.04.018_b0095","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1200\/JCO.2023.41.16_suppl.5012","article-title":"Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial","volume":"41","author":"Thiery-Vuillemin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.018_b0100","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.euo.2025.04.018_b0105","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(20)30449-6","article-title":"Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study","volume":"21","author":"Fizazi","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.04.018_b0110","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","article-title":"Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Fizazi","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.04.018_b0115","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.04.018_b0120","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.04.018_b0125","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ygyno.2022.06.028","article-title":"Impact of disease progression on health-related quality of life of advanced ovarian cancer patients\u2014pooled analysis from the PRIMA trial","volume":"166","author":"Chase","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.euo.2025.04.018_b0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0643","article-title":"Association of disease progression with health-related quality of life among adults with breast, lung, pancreatic, and colorectal cancer","volume":"3","author":"Marschner","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2025.04.018_b0135","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/cncr.33457","article-title":"Health-related quality-of-life assessment of patients with solid tumors on immuno-oncology therapies","volume":"127","author":"Voon","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2025.04.018_b0140","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eururo.2022.08.005","article-title":"Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort A study","volume":"83","author":"Yu","year":"2023","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:25:51Z","timestamp":1762629951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2588931125001129"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.018","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates and The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}